#1 Clinical Trials Search in Europe

Donanemab

Donanemab, also known as LY3002813, is an investigational drug being studied as a potential treatment for Alzheimer’s disease. This article explores the ongoing clinical trials evaluating donanemab’s safety, efficacy, and impact on brain amyloid plaques in patients with early symptomatic Alzheimer’s disease.

Table of Contents

What is Donanemab?

Donanemab, also known as LY3002813, is a new medication being developed to treat Alzheimer’s disease[1]. It is currently undergoing extensive clinical trials to evaluate its safety and effectiveness in treating early stages of Alzheimer’s disease[2]. Donanemab belongs to a class of drugs called monoclonal antibodies, which are designed to target specific proteins in the body.

How Donanemab Works

Donanemab works by targeting and removing amyloid plaques in the brain. Amyloid plaques are abnormal clumps of protein that accumulate in the brains of people with Alzheimer’s disease and are believed to contribute to the progression of the disease[2]. By clearing these plaques, donanemab aims to slow down or potentially halt the progression of Alzheimer’s disease symptoms.

Conditions Treated by Donanemab

Donanemab is primarily being studied for the treatment of:

  • Early symptomatic Alzheimer’s disease[2]
  • Mild Cognitive Impairment (MCI) due to Alzheimer’s disease[2]
  • Mild dementia due to Alzheimer’s disease[2]
These conditions represent the early stages of Alzheimer’s disease, where treatment may have the most significant impact on slowing disease progression.

Clinical Trials and Research

Donanemab is currently being studied in several large clinical trials, including:

  • TRAILBLAZER-ALZ 2: A Phase 3 study comparing donanemab to placebo in early symptomatic Alzheimer’s disease[3]
  • TRAILBLAZER-ALZ 3: A study evaluating donanemab in people with preclinical (very early) Alzheimer’s disease[4]
  • TRAILBLAZER-ALZ 4: A study comparing donanemab to another Alzheimer’s medication called aducanumab[2]
  • TRAILBLAZER-ALZ 5: A global study investigating the safety and efficacy of donanemab in early symptomatic Alzheimer’s disease[5]
These trials are designed to assess how well donanemab works in slowing cognitive decline, improving daily function, and clearing amyloid plaques from the brain.

How Donanemab is Administered

Donanemab is administered through intravenous (IV) infusion, which means it is given directly into a vein. The typical dosing schedule in clinical trials includes:

  • Initial doses of 700 mg every 4 weeks for the first three doses[2]
  • Followed by 1400 mg every 4 weeks for subsequent doses[2]
The exact dosing may vary depending on the specific clinical trial or treatment plan.

Effectiveness of Donanemab

Early clinical trial results have shown promising outcomes for donanemab:

  • Significant reduction in amyloid plaque levels in the brain[3]
  • Potential slowing of cognitive and functional decline compared to placebo[3]
  • Improvements in various cognitive and functional assessment scales, such as the Integrated Alzheimer’s Disease Rating Scale (iADRS) and the Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB)[3]
However, it’s important to note that research is ongoing, and the full extent of donanemab’s effectiveness is still being evaluated in larger, long-term studies.

Safety and Side Effects

As with any medication, donanemab may cause side effects. Some potential side effects being monitored in clinical trials include:

  • ARIA-E (Amyloid-Related Imaging Abnormalities-Edema): A type of swelling in the brain that can occur with amyloid-targeting treatments[6]
  • ARIA-H (Amyloid-Related Imaging Abnormalities-Hemorrhage): Small bleeds in the brain[6]
  • Infusion-related reactions[1]
Researchers are carefully monitoring these and other potential side effects to ensure the safety of participants in clinical trials.

Future Research and Ongoing Studies

Several ongoing and planned studies aim to further investigate donanemab:

  • Long-term safety and efficacy studies[7]
  • Comparison with other Alzheimer’s treatments[2]
  • Studies in different populations and stages of Alzheimer’s disease[4]
  • Real-world effectiveness studies[8]
These studies will help researchers better understand the potential benefits and risks of donanemab, as well as identify which patients may benefit most from this treatment.

Aspect Details
Drug Name Donanemab (LY3002813)
Target Condition Early symptomatic Alzheimer’s Disease (prodromal AD and mild dementia)
Administration Intravenous (IV) infusion
Primary Outcomes Change in cognitive and functional measures (iADRS, CDR-SB, MMSE)
Secondary Outcomes Amyloid plaque reduction, brain volume changes, safety profile
Trial Durations Typically 76 to 182 weeks, with some long-term extensions
Key Assessments Cognitive tests, PET scans, MRI, blood tests for pharmacokinetics
Safety Monitoring Adverse events, ARIA, anti-drug antibodies

FAQ

  • What is donanemab and how does it work? Donanemab is an investigational drug designed to target and remove amyloid plaques in the brain, which are believed to play a role in Alzheimer's disease. It is administered intravenously and aims to slow down the progression of cognitive decline associated with Alzheimer's.
  • What stage of Alzheimer's disease is donanemab being tested for? Donanemab is primarily being studied in patients with early symptomatic Alzheimer's disease, including those with mild cognitive impairment (MCI) and mild dementia due to Alzheimer's.
  • How is donanemab's effectiveness measured in clinical trials? The effectiveness of donanemab is measured using various cognitive and functional assessments, such as the Integrated Alzheimer's Disease Rating Scale (iADRS), Mini-Mental State Examination (MMSE), and Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB). Additionally, brain imaging techniques like amyloid PET scans are used to measure changes in amyloid plaque levels.
  • What are the potential side effects of donanemab? While specific side effects are still being studied, clinical trials are monitoring for adverse events, including a condition called ARIA (Amyloid-Related Imaging Abnormalities), which can involve brain swelling or small bleeds. The safety profile is being closely evaluated in ongoing studies.
  • How long do the clinical trials for donanemab typically last? The duration of donanemab clinical trials varies, but many last between 76 to 182 weeks (approximately 1.5 to 3.5 years). Some studies also include long-term extension periods to further evaluate the drug's efficacy and safety over time.

Ongoing Clinical Trials on Donanemab

  • Study on Donanemab, Florbetapir, and Flortaucipir for Patients with Early Alzheimer’s Disease

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Czechia The Netherlands Poland

  • A Study of Donanemab in People With Early Symptomatic Alzheimer’s Disease

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Poland Spain

  • Study on Donanemab Dosing for Adults with Early Alzheimer’s Disease

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

Glossary

  • Alzheimer's Disease (AD): A progressive brain disorder that slowly destroys memory and thinking skills, eventually affecting the ability to carry out simple tasks.
  • Amyloid Plaques: Abnormal clusters of protein fragments that build up between nerve cells in the brain, characteristic of Alzheimer's disease.
  • Donanemab: An investigational drug (also known as LY3002813) designed to target and remove amyloid plaques in the brain of Alzheimer's patients.
  • Mild Cognitive Impairment (MCI): A condition characterized by a slight but noticeable decline in cognitive abilities, often considered an early stage of Alzheimer's disease.
  • Positron Emission Tomography (PET) Scan: An imaging test that uses a radioactive tracer to visualize and measure activity in the brain, including the presence of amyloid plaques.
  • Integrated Alzheimer's Disease Rating Scale (iADRS): A combined assessment tool that measures both cognitive function and daily living activities in Alzheimer's patients.
  • Mini-Mental State Examination (MMSE): A brief test used to assess cognitive function, including orientation, memory, and language skills.
  • Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB): A scale used to evaluate cognitive and functional performance in six domains, providing a global assessment of dementia severity.
  • Amyloid-Related Imaging Abnormalities (ARIA): A potential side effect observed in some Alzheimer's treatments, involving brain swelling or small bleeds detected through imaging.
  • Intravenous (IV) Infusion: A method of administering medication directly into a vein using a needle or catheter.
  • Pharmacokinetics (PK): The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body over time.
  • Anti-Drug Antibodies (ADAs): Proteins produced by the immune system in response to a drug, which can potentially affect its efficacy or safety.

References

  1. https://clinicaltrials.gov/study/NCT05567159
  2. https://clinicaltrials.gov/study/NCT05108922
  3. https://clinicaltrials.eu/trial/study-on-donanemab-florbetapir-and-flortaucipir-for-patients-with-early-alzheimers-disease/
  4. https://clinicaltrials.gov/study/NCT05026866
  5. https://clinicaltrials.eu/trial/a-study-of-donanemab-in-people-with-early-symptomatic-alzheimers-disease/
  6. https://clinicaltrials.gov/study/NCT05738486
  7. https://clinicaltrials.gov/study/NCT04640077
  8. https://clinicaltrials.gov/study/NCT06566170